Topic
Every article tagged “Depression”, newest first.
248 articles · page 2 of 7 · Apr 16, 2026 – May 3, 2026
Archive summary Clinical
The U.S. Food and Drug Administration (FDA) on Thursday approved Axsome Therapeutics Inc.'s (NASDAQ: AXSM ) Auvelity (dextromethorphan HBr and bupropion HCl) for…
Archive summary Clinical
The first Phase 3 clinical trial of psilocybin for treatment-resistant depression has met its primary endpoint, marking a significant milestone for psychedelic…
Archive summary Clinical
Several million people are addicted to methamphetamines and also use tobacco, cannabis, alcohol, benzos, and opioids. Treatment is challenging. Mirtazapine could help.
Archive summary Clinical
(NaturalNews) A new study from researchers at APC Microbiome Ireland at University College Cork has found that regular coffee consumption is associated with measura...
Archive summary Clinical
(NaturalNews) The FDA announced accelerated review for three companies studying psilocybin and methylone as treatments for depression and PTSD. President Tru...
Archive summary Clinical
AtaiBeckley Inc. announced positive Phase 2a results for BPL-003, an intranasal treatment for treatment-resistant depression (TRD). The study found that 66.7% of…
Archive summary Clinical
A revolutionary depression treatment now available at Medical University of South Carolina delivers relief in days rather than months, offering hope for patients with…
Archive summary Clinical
AtaiBeckley Inc. presented promising clinical data on BPL-003 for treatment-resistant depression at the American College of Neuropsychopharmacology annual meeting, with…
Archive summary Clinical
Archive summary Clinical
The FDA's Marty Makary fast-tracked research for three companies to make psychedelic treatments for mental illness.
Archive summary Clinical
Psilocybin, the active ingredient in magic mushrooms, is moving into the mainstream.
Archive summary Clinical
A weekly roundup of policy news in the chemical arena and beyond
Archive summary Clinical
(NaturalNews) Introduction: The Empowering News for a Brighter MoodFor anyone who's ever felt their mood dip and instinctively known their food could be part of t...
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine ...
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its national network of ...
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing ...
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to ...
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its…
Archive summary Clinical
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central…
Archive summary Clinical
(The Center Square) – Some say President Donald Trump’s new executive order on psychedelics goes too far, while others say it’s a good first step, but more action is…
Archive summary Clinical
Strasbourg, France and Charleroi, Belgium, 22 April 2026 (0830 CET) – Elkedonia, a biotech company pioneering a novel neuroplastogen approach to develop therapeutics for…
Archive summary Clinical
NRx Pharmaceuticals has received a positive Discipline Review Letter from the FDA Office of Generic Drugs and completed a supportive meeting with Generic Drug…
Archive summary Clinical
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central…
Archive summary Clinical
Archive summary Clinical
“The research is clear about one thing: Recovery is not primarily a pharmacological event,” write Dimitri Mugianis and Ross Ellenhorn.
Archive summary Clinical
Shares of psychedelic drug developers rose after Trump signed an executive order directing health regulators to speed up reviews of treatments.
Archive summary Clinical
A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for…
Archive summary Clinical
LONDON & NEW YORK--(BUSINESS WIRE) $CMPS Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based…
Archive summary Clinical
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR…
Archive summary Clinical
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies Company's clinical research operations and therapist training programs directly positioned to…
Archive summary Clinical
In the trial’s overall (intent-to-treat) study population, daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated…
Archive summary Clinical
The latest chapter in Dr. Sanjay Gupta’s “Weed” documentary showed him that cannabis has become a lifeline for countless women who feel unseen by...
Archive summary Clinical
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science…
Archive summary Clinical
Archive summary Clinical
President Donald Trump signed an executive order to expedite the FDA review of psychedelic drugs for treating PTSD and traumatic brain injuries in military veterans,…
Archive summary Clinical
EINPresswire/ -- Depression affects more than 2.5 million Canadians each year, and for many, medications alone aren't enough. NextWave TMS, a pioneering mental health…
Archive summary Clinical
Research shows mental health problems account for about 23% of maternal deaths in the country.
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems…
Archive summary Clinical
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems…
Archive summary Clinical
Mental health experts say 1 in 10 men suffer from paternal postpartum depression, and it is not a sign that you don't love your baby or partner.